GlassScriptPhysician profile
Jessica Macwan
NPI 1275308314
$1,962.44
in general payments reported to CMS, 2019-2025
23 companies · $994 in 2025
The $994 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $969 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $412.87 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Corium, LLC | $222.87 | 2024-2025 | Azstarys |
| Abbott Laboratories | $127.43 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $80.96 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $61.99 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $60.95 | 2025 | |
| Phathom Pharmaceuticals, INC. | $60.73 | 2024-2025 | Voquezna |
| Dexcom, INC. | $48.69 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $42.69 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $41.81 | 2025 | |
| Seqirus USA INC | $34.60 | 2025 | Flucelvax, Fluad |
| Lilly USA, LLC | $33.54 | 2024-2025 | Jardiance, Zepbound |
| Antares Pharma, INC. | $31.38 | 2024 | Xyosted |
| Avvisto Therapeutics, LLC | $22.83 | 2025 | Cycloset |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.88 | 2024 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2024 | Crysvita |
| Dynavax Technologies Corporation | $17.14 | 2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $16.13 | 2024 | Gemtesa |
| Astellas Pharma US INC | $15.78 | 2025 | Veozah |
| Pfizer INC. | $15.37 | 2025 | |
| Ardelyx, INC. | $13.65 | 2024 | Ibsrela |
| Tolmar, INC. | $13.47 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Macwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.